Elanco reported continued underlying revenue growth in 2025 and outlined 2026 guidance calling for mid-single-digit organic revenue gains and higher profit growth as innovation scales.
Elanco has received USDA approval for TruCan™ Ultra B (Oral), the first ½ mL oral Bordetella bronchiseptica vaccine for dogs, designed to deliver proven protection with improved patient comfort.
Elanco Animal Health will report fourth quarter and full-year 2025 financial results on February 24, 2026, followed by a conference call with investors and media.
Elanco Animal Health has received U.S. Department of Agriculture (USDA) approval for Befrena™ (tirnovetmab), an anti-IL31 monoclonal antibody injection providing long-lasting relief for dogs suffering from allergic and atopic dermatitis.
Elanco Animal Health has received full approval from the U.S. Department of Agriculture for Trutect™ (formerly CPMA), the first and only monoclonal antibody therapy proven to treat—and now prevent—deadly canine parvovirus.
Elanco Animal Health reported third quarter 2025 revenue of $1.14 billion, up 10% year-over-year, with 9% organic constant currency growth, driven by pet health and farm animal performance. The company raised full-year guidance and innovation revenue targets.
The FDA has approved expanded labels for Elanco’s Credelio™ and Credelio Quattro™, adding prevention of Lyme disease and protection against the rapidly spreading longhorned tick—now found in 22 U.S. states.
The FDA has granted an Emergency Use Authorization for Elanco’s Credelio™ (lotilaner) to treat New World screwworm infestations in dogs—marking the first authorization of its kind as the parasite nears the U.S. border.